Sandoz aims to become the leading European generic supplier of semaglutide as the drug’s patents gradually lose protection, finance chief Remco Steenbergen told Handelsblatt.
Patent expiry opens a multi‑billion‑dollar generic market
Semaglutide – the active ingredient in Novo Nordisk’s weight‑loss injections – is described by Handelsblatt as “one of the most significant patent expiries in the history of the pharmaceutical industry.” The German article notes that the patents are “gradually losing protection,” which will allow cheaper copies to enter the market.
For investors and health‑policy watchers the timing is crucial: each patent lapse creates a window for generic manufacturers to file applications and launch products. The article does not give a precise timetable for each expiry, but the phrasing “gradually losing protection” signals a phased rollout rather than a single date.
Sandoz’s strategy and leadership
Sandoz, a Swiss subsidiary of Novartis, is headquartered in Basel and employs roughly 5,724 people according to Wikidata. The company was founded in 1886 and operates in the pharmaceutical industry, focusing on generic medicines and biosimilars. While the packet does not confirm the current chief executive, it does identify Remco Steenbergen as finance chief, the source of the strategic comment.
Steenbergen’s statement to Handelsblatt – “Allen voran der Schweizer Konzern Sandoz, der sich als führender Anbieter etablieren will” – makes clear that the ambition is to be the primary supplier, not merely a participant. The ambition is framed as a response to a “multi‑billion‑dollar” opportunity, implying that the generic version of semaglutide could capture a sizable share of the weight‑loss market once price pressures increase.
Sector implications and competitive landscape
Novo Nordisk, the originator of semaglutide, is a Danish pharmaceutical group headquartered in Bagsværd. It employs about 42,446 people and is listed on the NYSE under ticker NVO. The company’s recent filings (Form 6‑K in September 2026) do not mention a defensive strategy for the upcoming patent expiries, leaving the market open for challengers.
Should Sandoz secure a leading position, the competitive dynamics in Europe could shift. Generic entrants typically drive down prices, expanding patient access but compressing margins for originators. For health‑care payers, a lower‑cost generic could ease budget pressures, especially as obesity‑related treatments become more widely prescribed.
Other European generics firms – such as Teva, Mylan (now part of Viatris) and the UK‑based Accord – are also monitoring the patent landscape. The packet does not provide statements from these rivals, so their exact plans remain unknown.
What remains unknown
- The precise schedule of each semaglutide patent expiry in Europe.
- Whether Novo Nordisk will launch authorized generics or pursue settlement agreements.
- The pricing strategy Sandoz will adopt for its generic version.
- The regulatory timeline for approval of a generic semaglutide product.
Until those details emerge, investors will have to watch filings, regulatory updates and any further comments from Sandoz’s senior management.
Company snapshot
| Company | Headquarters | Employees | Founded |
|---|---|---|---|
| Sandoz | Basel, Switzerland | 5,724 | 1886 |
| Novo Nordisk | Bagsværd, Denmark | 42,446 | 1923‑01‑01 |
| Sources: Wikidata entries for Sandoz (Q528468) and Novo Nordisk (Q818846); SEC Form 6‑K filings, September 2026. | |||
In the weeks ahead, the market will gauge how quickly Sandoz can translate its stated ambition into a commercial product. The next patent expiry milestone will be the first test of whether the Swiss firm can indeed become Europe’s leading generic semaglutide supplier.